What is the fair value of Evolus Inc (NASDAQ-EOLS) stock?

The current fair value estimate for Evolus Inc (NASDAQ-EOLS) is $6.24. This implies an estimated upside of 6.9% versus the current market price.

Is Evolus Inc (NASDAQ-EOLS) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 6.9% versus the current market price.

What is the analyst price target for NASDAQ-EOLS stock?

The available analyst price target for Evolus Inc (NASDAQ-EOLS) is $14.67. The analyst target implies estimated upside of 151.1%.

How is the financial health of Evolus Inc?

The current financial health read for Evolus Inc (NASDAQ-EOLS) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Evolus Inc's next earnings date?

The next earnings date currently listed for Evolus Inc (NASDAQ-EOLS) is August 5, 2026.

Does Evolus Inc (NASDAQ-EOLS) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for Evolus Inc (NASDAQ-EOLS)?

The current P/E ratio listed for Evolus Inc (NASDAQ-EOLS) is -8.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Evolus Inc?

The current market capitalization listed for Evolus Inc is 365.2 M.

What is the enterprise value of Evolus Inc?

The current enterprise value listed for Evolus Inc is 489.8 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Evolus Inc?

The ticker symbol for Evolus Inc is NASDAQ-EOLS, and the stock is listed on NASDAQ.

Where is Evolus Inc (NASDAQ-EOLS) listed?

Evolus Inc (NASDAQ-EOLS) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Evolus Inc?

The current debt-to-total-capital ratio listed for Evolus Inc is 31.1%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Evolus Inc?

The free float listed for Evolus Inc is 76.0%. Free float helps investors understand how much of the share base is available for public trading.

Evolus Inc (EOLS) Fair Value & Stock Analysis

Evolus Inc (EOLS)

Evolus, Inc. is a healthcare company listed on NASDAQ under the ticker EOLS. The company focuses on the cash-pay aesthetic market and markets its products in the United States, Canada, Europe, and Australia. Its portfolio includes Jeuveau, a purified botulinum toxin type A formulation used for the temporary improvement of moderate to severe glabellar lines in adults, and Evolysse, a range of injectable hyaluronic acid gels designed for areas such as the mid face, nasolabial folds, lips, and eyes. Evolus was incorporated in 2012 and is headquartered in Newport Beach, California.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
NASDAQ-EOLS	$6.24	6.9% Upside	Fair	$14.67	151.1% Upside	Bargain	Fair	—	—	—	0.0%	August 5, 2026	-8.6x	-13.0x	1.2x	365.2 M	489.8 M	31.1%	76.0%	-3.4	—	92.4%